A Clinical Appraisal of Pentapyrrolidinium (M&B 2050) in Hypertensive Patients

Digital Record

Identifier: 101584929X43

Staff Only

Digital Object (text)

Go to file

Dates

Publication: April 1954

Extent

7 pages

Creator

Freis, Edward D. (Creator, Person)

Description

Here, Freis's team studied the effectiveness of pentapyrrolidinium (a ganglionic-blocking agent, also called pentolinium) as an antihypertensive treatment. They concluded that the drug had several advantages in the treatment of severe hypertension over another ganglionic-blocking agent, hexamethonium. The drug's attributes, longer duration of action, greater potency, and a more uniform response to oral administration, more than compensated for its side effects and the frequent need to adjust dosage.

Language of Materials

English

Additional Description

Original Profiles System Identifier

XFBBDB

Source Category

Periodical

Freis, Edward D., Edward A. Partenope, Lawrence S. Lilienfield, and John C. Rose. "A Clinical Appraisal of Pentapyrrolidinium (M&B 2050) in Hypertensive Patients." Circulation IX, 4 (April 1954): 540-546. Article. 7 Images.

Circulation